Carnitine for the Treatment of Atherosclerosis.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 177 participants.

Also called NCT02117661

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 177 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02117661
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02117661. Randomized; double masking; primary purpose treatment. Start 2015-01 (actual); primary completion 2017-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Carnitine for the Treatment of Atherosclerosis.
Acronym
ECoM
Intervention (Dietary supplement)
L-carnitine capsules
Intervention (Dietary supplement)
Cellulose capsules
Lead sponsor
Dr. Amer Johri (class: other)
Collaborator
Heart and Stroke Foundation of Canada (class: other)
Collaborator
Queen's University (class: other)

Record details

Record id
cardio:ct-nct02117661
Content hash
75fa21d432f3e23a8cf1506ffbbb8acb22e2b4c74cf289d00185c151e00b77bb